Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis - Archive ouverte HAL Access content directly
Journal Articles Therapeutic Drug Monitoring Year : 2017

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis

, , (1) , (1) , (2) , (1)
1
2

Abstract

Treatment of spondyloarthritis (SpA) has greatly improved in the biopharmaceutical era. These compounds, primarily tumor necrosis factor inhibitors, are effective, but some patients may show poor response, sometimes due to the presence of antidrug antibodies (ADAs). In some instances, clinicians may increase or taper the dose, depending on the clinical response. Besides the current clinical practice, a tailored strategy based on drug monitoring is emerging as a way to improve the use of these drugs. However, the relevance of this therapeutic drug monitoring of biopharmaceuticals for SpA is still unknown. In this literature review, we examined the most relevant articles dealing with the concentration-response relation, ADA detection, and pharmacokinetics in SpA treated with biopharmaceuticals. ADAs were associated with low or undetectable concentration of monoclonal antibodies. The relation between drug concentration and clinical response in SpA is debated, some studies showing an association and others not. Therefore, therapeutic drug monitoring of biopharmaceuticals for SpA requires a better understanding of the association among the pharmacokinetics, pharmacodynamics, and immunogenicity of these drugs.
Not file

Dates and versions

hal-01980745 , version 1 (14-01-2019)

Identifiers

Cite

Frédéric Medina, Chamaida Plasencia, Philippe Goupille, Gilles Paintaud, Alejandro Balsa, et al.. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis. Therapeutic Drug Monitoring, 2017, 39 (4), pp.360-363. ⟨10.1097/FTD.0000000000000400⟩. ⟨hal-01980745⟩

Collections

UNIV-TOURS CNRS
27 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More